RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

On March 21, 2020, the Company entered into five separately negotiated Exchange Agreements (each an “Exchange Agreement” and collectively, the “Exchange Agreements”) with certain existing holders (the “Noteholders”) of Convertible Promissory Notes of the Company (the “Notes”). On March 22, 2020 (the “Closing Date”), each Noteholder exchanged his, her or its Note or Notes for shares of common stock of the Company (“Common Stock”) as contemplated by the respective Exchange Agreement. The Noteholders had purchased the Notes from the Company on one or more of the following dates: December 31, 2014, December 6, 2018, December 7, 2018, February 27, 2019, March 6, 2019 and March 14, 2019. Under the Exchange Agreements, an aggregate of $255,786.37 principal amount and accrued interest with respect to the Notes were exchanged and cancelled in return for an aggregate of 17,052,424 shares of Common Stock.

A description and form of each Note that was exchanged under the Exchange Agreements can be found in the Company’s Current Reports on Form 8-K filed on January 7, 2015, December 17, 2018, and March 5, 2019.

This description of the Exchange Agreements does not purport to be complete and is qualified in its entirety by reference to the form of Exchange Agreement, a copy of which is attached to this Current Report on Form 8-K as Exhibit 99.1. The information set forth in Item 3.02 herein is incorporated into this Item 1.01 by reference.

2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.

Under the terms of certain other Convertible Promissory Notes of the Company issued in April, May, August, October and November of 2019 (the “Subsequent Notes”), as disclosed on the Company’s Current Reports on Form 8-K filed on April 30, 2019, May 23, 2019, August 27, 2019, October 28, 2019 and November 5, 2019, the Company is subject to covenants to maintain a number of reserved shares of Common Stock with respect to these Subsequent Notes. The reserve requirement is generally a multiple of the number of shares of Common Stock that would be issued if there were a conversion to the terms of the applicable Subsequent Note. A breach by the Company of these covenants is an event of default under the terms of the April, August and October Subsequent Notes that generally increases the applicable note’s principal amount and interest rate, and accelerates its maturity date, making the debt immediately due and payable. For the May Subsequent Note, the provisions are similar, but a notice of default is required before such increases and acceleration, which, as of the filing of this Current Report on Form 8-K, the Company had not received. For the November Subsequent Note, an event of default will only occur if the holder requests replenishment of the reserves, and that request is not met within three days or a subsequent five day cure period. The holder of the November Subsequent Note has not yet made such request. In addition, on March 26, 2020 the holders of the August and October Subsequent Notes agreed to waive the event of default until April 30, 2020, by which time the Company expects to have completed the filing with respect to the increase in authorized shares, as discussed under Item 8.01 below.

The issuances of Common Stock described in Item 1.01 and Item 5.02 herein reduced the number of shares of Common Stock to a level below what is required by the covenants in the Subsequent Notes, resulting in a breach and event of default, as described above, of the Subsequent Notes. The Company is currently seeking waivers with respect to the reserve requirements and the default provisions related thereto from the holders of the Subsequent Notes until the Amendment (as defined below) is effective. There can be no assurance that such holders will agree to such waivers.

On March 26, 2020, the holder of the April Subsequent Note converted the remaining outstanding principal under the note into shares, to the terms of the note. That note is now repaid in full and no ongoing default exists thereunder. Similarly, several of the holders of Subsequent Notes have been converting repeatedly over the past several days. These ongoing conversions make it difficult to calculate precisely the amounts currently outstanding under the Subsequent Notes, but the amounts outstanding as of the date hereof are approximately $375,000 in the aggregate.

As is disclosed in Item 8.01 below, the board of directors of Company approved, and the holders of a majority of the outstanding shares of the Company’s Common Stock executed written consents approving an Amendment (as defined below) to the Company’s Certificate of Incorporation. When filed with the Secretary of State of Delaware, the Amendment will increase the number of authorized shares of Common Stock, with the intention of reestablishing the Company’s compliance with the share reserve covenants contained in the Subsequent Notes. The Company has taken this action primarily to increase the number of authorized shares available and to bring it back into compliance with the covenants in the Subsequent Notes regarding the required number of reserved shares of Common Stock. The outstanding principal of certain of the Subsequent Notes has been reduced as the holders of these notes have converted a portion of the outstanding principal in exchange for Common Shares, to the term of the applicable Subsequent Note. With respect to those Subsequent Notes for which conversions have occurred, interest continues to accrue based upon the reduced principal amount of the relevant Subsequent Note. As noted above, the Company is in discussions with the holders of the Subsequent Notes with respect to this recent action, seeking waivers regarding the technical breach of the reserve provisions until such time as the increase in authorized shares is effective, which the Company currently expects will be in late April 2020, and the number of reserved shares is again in compliance with the applicable covenants.

The description of the Subsequent Notes does not purport to be complete and is qualified in its entirety by reference to the descriptions and forms thereof in the Company’s Current Reports on Form 8-K filed on April 30, 2019, May 23, 2019, August 27, 2019, October 28, 2019 and November 5, 2019.

Item 3.02 Unregistered Sales of Equity Securities.

The information set forth in Item 1.01 and Item 5.02 herein is incorporated into this Item 3.02 by reference.

The Noteholders made representations to the Company in the Exchange Agreements that they met the accredited investor definition of Rule 501 of Regulation D of the Securities Act of 1933, as amended (the “Securities Act”), and the Company relied on such representations.

The transactions described in Item 1.01 and Item 5.02 herein were between the Company and its existing security holders and were made in reliance on the exemption from registration afforded by Section 3(a)(9), or alternatively Section 4(a)(2), of the Securities Act. These transactions were not conducted in connection with a public offering and the participants in these transactions did not rely on, and the Company did not make, any public solicitation or advertisement in connection with these transactions.

This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 21, 2020, Jeff E. Margolis and Dr. Arnold Lippa, each a director and officer of the Company, agreed to forgive a portion of the accrued but unpaid compensation to which each was entitled to his employment agreement with the Company, equal to $153,000 each. On March 22, 2020, the Company issued to each of Mr. Margolis and Dr. Lippa 4,500,000 shares of Common Stock in exchange for this forgiveness, which equates to a per share value of $0.034 per share, the closing share price of Common Stock on Friday, March 20, 2020, the last business day prior to the transaction.

Item 8.01 Other Events.

On March 21, 2019, the board of directors of the Company approved a Certificate of Amendment to the Company’s Certificate of Incorporation (the “Amendment”) that would increase the number of authorized shares of Common Stock from 65,000,000 to 1,000,000,000. On March 22, 2019, a majority of the holders of Common Stock approved the Amendment by written consent, which constituted a majority of the Company’s outstanding stock entitled to vote on the increase as well as a majority of Common Stock voting as a separate class, as is required for such approval under the General Corporation Law of the State of Delaware. Further information on the Amendment, including a form of the Amendment, and its approval can be found in the Preliminary Information Statement on Schedule 14C filed by the Company on March 24, 2020. This information may be supplemented or revised in the Definitive Information Statement, which the Company currently expects to file in early April 2020 in accordance with the applicable rules regarding such filings promulgated by the Securities and Exchange Commission.

The Company will file the Amendment with the Secretary of State of the State of Delaware, and the Amendment will become effective, no earlier than 20 days after the Definitive Information Statement is first mailed to stockholders, as required by Rule 14c-2 of the Securities Exchange Act of 1934, as amended. The Company currently expects to make this filing in late April 2020.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1*	Form of Exchange Agreement.

* filed herewith

RespireRx Pharmaceuticals Inc. Exhibit
EX-99.1 2 ex99-1.htm   Exhibit 99.1   EXCHANGE AGREEMENT   [Name] (the “Holder) enters into this Agreement (the “Agreement”) with RespireRx Pharmaceuticals Inc.,…
To view the full exhibit click here

About RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI)

RespireRx Pharmaceuticals Inc., formerly Cortex Pharmaceuticals, Inc., is engaged in the discovery, development and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The Company is focused on the clinical development in the areas of respiratory disorders, including respiratory depression and sleep apnea. It is engaged in research and clinical development of a class of compounds referred to as ampakines, which act to enhance the actions of the excitatory neurotransmitter glutamate at a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors. Its ampakines, including CX717, CX1739 and CX1942, were efficacious in treating drug induced respiratory depression caused by opioids or certain anesthetics without offsetting the analgesic effects of the opioids or the anesthetic effects of the anesthetics. Its dronabinol is indicated for the treatment of sleep-related breathing disorders, including sleep apnea.